U.S. Markets closed

How Is Gilead Sciences Revamping Its NASH Strategy in 2019?

Margaret Patrick
How Is Gilead Sciences Revamping Its NASH Strategy in 2019?

Gilead Sciences or Biogen: Which Is the Better Biotech Pick?(Continued from Prior Part)NASH failed trialsOn February 11, Gilead Sciences (GILD) issued a press release announcing the top line results from its Phase 3 STELLAR-4 study evaluating the